Qiagen
| Company type | Public (Naamloze vennootschap) |
|---|---|
| ISIN | NL0015001WM6 |
| Industry | Biotechnology |
| Founded | November 29, 1984 |
| Founders |
|
| Headquarters | |
Key people |
|
| Revenue | US$1.97 billion (2023) |
| US$410 million (2023) | |
| US$341 million (2023) | |
| Total assets | US$6.12 billion (2023) |
| Total equity | US$3.81 billion (2023) |
Number of employees | 5,967 (2023) |
| Website | qiagen |
| Footnotes / references | |
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. QIAGEN's shares are listed at the NYSE (using ticker QGEN) and at the Frankfurt Stock Exchange in the Prime Standard (using ticker QIA). Thierry Bernard is the company's Chief Executive Officer (CEO).